Foamix Pharmaceuticals Ltd. (FOMX) Scheduled to Post Quarterly Earnings on Tuesday

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) will announce its earnings results after the market closes on Tuesday, November 14th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.05). Foamix Pharmaceuticals had a negative net margin of 823.74% and a negative return on equity of 39.20%. The business had revenue of $0.80 million during the quarter, compared to analyst estimates of $1.50 million. During the same quarter last year, the company posted ($0.27) earnings per share. The company’s revenue was up 6.7% on a year-over-year basis. On average, analysts expect Foamix Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foamix Pharmaceuticals Ltd. (NASDAQ FOMX) opened at $5.59 on Friday. Foamix Pharmaceuticals Ltd. has a one year low of $4.03 and a one year high of $11.27.

ILLEGAL ACTIVITY WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/11/12/foamix-pharmaceuticals-ltd-fomx-scheduled-to-post-quarterly-earnings-on-tuesday.html.

A number of equities research analysts have issued reports on FOMX shares. Credit Suisse Group reiterated a “buy” rating and set a $9.00 price objective on shares of Foamix Pharmaceuticals in a research note on Wednesday, July 19th. HC Wainwright started coverage on shares of Foamix Pharmaceuticals in a research note on Thursday, August 24th. They set a “buy” rating and a $12.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply